Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, ...
Examining protein changes in peripheral blood cells just 24 hours after initiating chemotherapy for acute myeloid leukemia (AML) could predict 5-year overall survival, potentially allowing treatment ...
Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...
Your bone marrow is supposed to be your body’s reliable blood cell factory, churning out healthy red cells, white cells, and platelets like clockwork. But sometimes this vital production system goes ...
Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...
Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute ...
The refusal of blood transfusions by Jehovah’s Witnesses poses a major challenge in treating acute myeloid leukaemia (AML), ...
Discusses Clinical Update on AB8939 Combined With Venetoclax for Refractory and Relapsed AML With Poor Genetics October 16, ...
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback